Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials

Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials

Abstract Background Individualized prediction of treatment response may improve the value proposition of advanced treatment options in severe asthma. This study aimed to investigate the combined capacity of patient characteristics in predicting treatment response to mepolizumab in patients with seve...

Full description

Bibliographic Details
Main Authors: Wenjia Chen, Helen K. Reddel, J Mark FitzGerald, Richard Beasley, Christer Janson, Mohsen Sadatsafavi
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Respiratory Research
Subjects:
Severe asthma
Biologics
Mepolizumab
Prediction
Treatment response
Online Access:https://doi.org/10.1186/s12931-023-02409-2

Internet

https://doi.org/10.1186/s12931-023-02409-2

Similar Items